# √âvaluation et Recommandations d'Am√©lioration - Fichiers Canonical

**Date**: 2026-02-03  
**Contexte**: Analyse post-test E2E v13 (29 items)  
**Objectif**: Am√©liorer qualit√© ingestion, normalisation et domain scoring via fichiers canonical uniquement  
**P√©rim√®tre**: Modifications SANS toucher au code Lambda

---

## üìä SYNTH√àSE EX√âCUTIVE

### R√©sultats Test E2E v13
- **Items trait√©s**: 29 items
- **Items match√©s**: 14 (48%)
- **Probl√®mes identifi√©s**: 7 cas critiques n√©cessitant corrections

### Probl√®mes Critiques Identifi√©s

| # | Probl√®me | Type | Impact | Priorit√© |
|---|----------|------|--------|----------|
| 1 | Faux positifs "manufacturing injectable" | Scoring | Bruit newsletter | üî¥ HAUTE |
| 2 | Mots-cl√©s LAI non d√©tect√©s ("once-weekly", "once-monthly") | Normalisation | Faux n√©gatifs | üî¥ HAUTE |
| 3 | Hallucinations Bedrock (microspheres non mentionn√©es) | Prompt | Confiance scoring | üü† MOYENNE |
| 4 | URL alternative non ing√©r√©e (FierceBiotech) | Ingestion | Perte contenu riche | üü† MOYENNE |
| 5 | R√©sultats financiers pure players match√©s | Scoring | Bruit newsletter | üü° BASSE |
| 6 | Signaux "hybrid company" trop g√©n√©riques | Scoring | Faux positifs | üü° BASSE |
| 7 | Contenu HTML incomplet (extraction partielle) | Ingestion | Perte signaux | üü† MOYENNE |

---

## üîç ANALYSE D√âTAILL√âE PAR √âTAPE

### 1. INGESTION

#### 1.1 Probl√®me: URL Alternative Non Ing√©r√©e

**Cas**: AstraZeneca/CSPC partnership
- ‚ùå **Ing√©r√©**: `endpoints.news` (contenu minimal)
- ‚úÖ **Manqu√©**: `fiercebiotech.com` (contenu riche avec "once-monthly dosing platform")

**Cause**: Source catalog ne liste qu'une URL par source

**Impact**: Perte de signaux LAI critiques pr√©sents dans version alternative

**Recommandation**: 
```yaml
# Ajouter dans source_catalog.yaml
alternative_urls:
  - url: "https://www.fiercebiotech.com/"
    priority: "high"
    reason: "Contenu plus d√©taill√© que Endpoints"
```

#### 1.2 Probl√®me: Extraction HTML Incompl√®te

**Cas**: Plusieurs items corporate avec contenu tronqu√©

**Cause**: `max_content_length: 1000` trop restrictif

**Recommandation**:
```yaml
# Dans source_catalog.yaml - sources corporate
max_content_length: 2000  # Augmenter de 1000 ‚Üí 2000
content_enrichment: "full_article"  # Au lieu de "summary_enhanced"
```

#### 1.3 Probl√®me: Bruit Financier/RH Non Filtr√©

**Cas**: 
- "Publication of 2026 financial calendar" (MedinCell)
- "Medincell to Join MSCI World Small Cap Index"
- "Nanexa publishes interim report"

**Cause**: Profil `corporate_pure_player_broad` trop permissif

**Recommandation**:
```yaml
# Dans ingestion_profiles.yaml
corporate_pure_player_broad:
  exclusion_scopes:
    - "exclusion_scopes.financial_reporting_terms"  # ‚úÖ D√©j√† pr√©sent
    - "exclusion_scopes.stock_market_terms"  # üÜï AJOUTER
```

**Nouveau scope √† cr√©er**:
```yaml
# Dans exclusion_scopes.yaml
stock_market_terms:
  description: "Termes boursiers/indices sans contenu LAI"
  keywords:
    - "MSCI"
    - "stock index"
    - "market cap"
    - "financial calendar"
    - "interim report"
    - "quarterly report"
    - "half-year results"
    - "consolidated results"
```

---

### 2. NORMALISATION

#### 2.1 Probl√®me CRITIQUE: Mots-Cl√©s LAI Non D√©tect√©s

**Cas 1**: Novo Nordisk CagriSema
- **Texte source**: "A **once-weekly shot** of CagriSema"
- **D√©tect√©**: ‚ùå Aucun signal LAI
- **Attendu**: ‚úÖ `once-weekly` = MEDIUM signal

**Cas 2**: Quince steroid therapy
- **Titre**: "experimental **once-monthly** steroid-based treatment"
- **D√©tect√©**: ‚ùå Aucun signal LAI
- **Attendu**: ‚úÖ `once-monthly` = MEDIUM signal

**Cause**: Prompt normalisation ne demande PAS explicitement d'extraire dosing intervals

**Impact**: Faux n√©gatifs sur items LAI l√©gitimes

**Recommandation CRITIQUE**:

```yaml
# Dans generic_normalization.yaml
user_template: |
  4. ENTITY EXTRACTION (ALL explicitly mentioned)
     - Companies: ALL pharmaceutical/biotech company names
     - Molecules: ALL drug/molecule names (INN, generic names)
     - Technologies: ALL technology keywords (e.g., "microspheres", "PEGylation")
     - Trademarks: ALL commercial product names (e.g., "UZEDY¬Æ", "Ozempic")
     - Indications: ALL therapeutic indications/diseases mentioned
     - Dosing Intervals: ALL dosing frequency terms (e.g., "once-weekly", "once-monthly", "q4w", "quarterly")  # üÜï AJOUTER
```

**Ajout dans response format**:
```json
{
  "dosing_intervals_detected": ["once-weekly", "once-monthly"]  // üÜï AJOUTER
}
```

#### 2.2 Probl√®me: Hallucinations Bedrock

**Cas**: AstraZeneca/CSPC
- **Bedrock dit**: "Microsphere technology mentioned"
- **Texte r√©el**: Aucune mention de "microspheres"

**Cause**: Prompt scoring trop permissif, Bedrock inf√®re au lieu d'extraire

**Recommandation**:

```yaml
# Dans lai_domain_scoring.yaml
system_instructions: |
  CRITICAL RULES:
  1. Only detect signals EXPLICITLY present in the text
  2. DO NOT infer or hallucinate signals
  3. If a technology is not mentioned by name, do NOT add it to signals_detected
  4. Base your evaluation ONLY on normalized entities provided
```

---

### 3. DOMAIN SCORING

#### 3.1 Probl√®me: Faux Positifs "Manufacturing Injectable"

**Cas**: Eli Lilly manufacturing facilities
- **Texte**: "manufacturing facility for injectable drugs and devices"
- **Score**: 80/100 (MATCH√â)
- **Attendu**: 0 (NON MATCH√â)

**Cause**: Signal "hybrid_company: Eli Lilly" suffit pour scorer haut

**Recommandation**:

```yaml
# Dans lai_domain_definition.yaml
exclusions:
  - "oral tablet"
  - "oral capsule"
  # ... existants
  - "manufacturing facility"  # üÜï AJOUTER
  - "production plant"  # üÜï AJOUTER
  - "factory construction"  # üÜï AJOUTER

# Nouvelle r√®gle de contexte
context_rules:
  - id: rule_manufacturing_only
    condition: "event_type == 'corporate_move' AND ('manufacturing' OR 'factory' OR 'plant') AND NO technology_signals"
    action: "reject (manufacturing without LAI technology)"
```

#### 3.2 Probl√®me: R√©sultats Financiers Pure Players

**Cas**: MedinCell financial results
- **Score**: 55/100 (MATCH√â)
- **Attendu**: 0 (NON MATCH√â)

**Cause**: `event_type: financial_results` a base_score = 30, pure player boost = 25 ‚Üí Total 55

**Recommandation**:

```yaml
# Dans lai_domain_definition.yaml
scoring:
  event_type_base_scores:
    financial_results: 0  # üîß MODIFIER: 30 ‚Üí 0
    
  # Nouvelle r√®gle stricte
  event_type_requirements:
    financial_results:
      require_signals: ["strong", "medium"]  # üÜï AJOUTER
      min_signal_count: 2
      reasoning: "Financial results need explicit LAI content to be relevant"
```

#### 3.3 Probl√®me: Signaux "Hybrid Company" Trop G√©n√©riques

**Cas**: Eli Lilly, Novo Nordisk match√©s sans contenu LAI

**Cause**: Signal "hybrid_company" donne +10 points m√™me sans contexte LAI

**Recommandation**:

```yaml
# Dans lai_domain_definition.yaml
scoring:
  entity_boosts:
    hybrid_company: 5  # üîß MODIFIER: 10 ‚Üí 5 (r√©duire poids)
    
  # Nouvelle r√®gle de combinaison
  boost_combination_rules:
    - id: hybrid_company_boost
      condition: "hybrid_company detected"
      requires_additional: ["technology_family", "dosing_interval", "key_molecule"]
      reasoning: "Hybrid companies need LAI-specific context"
```

---

## üìã PLAN D'AM√âLIORATION PRIORIS√â

### Phase 1: Corrections Critiques (Impact Imm√©diat)

**Priorit√© üî¥ HAUTE - √Ä faire en premier**

1. **Normalisation: Ajouter extraction dosing intervals**
   - Fichier: `canonical/prompts/normalization/generic_normalization.yaml`
   - Changement: Ajouter `dosing_intervals_detected` dans extraction
   - Impact: R√©sout faux n√©gatifs CagriSema, Quince

2. **Scoring: Exclure manufacturing sans tech LAI**
   - Fichier: `canonical/domains/lai_domain_definition.yaml`
   - Changement: Ajouter exclusions manufacturing + r√®gle contextuelle
   - Impact: R√©sout faux positifs Eli Lilly

3. **Scoring: R√©duire poids financial_results**
   - Fichier: `canonical/domains/lai_domain_definition.yaml`
   - Changement: `financial_results: 30 ‚Üí 0`
   - Impact: R√©sout faux positifs MedinCell financial

### Phase 2: Am√©liorations Qualit√© (Impact Moyen)

**Priorit√© üü† MOYENNE**

4. **Ingestion: Filtrer bruit boursier**
   - Fichier: `canonical/scopes/exclusion_scopes.yaml`
   - Changement: Cr√©er `stock_market_terms` scope
   - Impact: R√©duit bruit corporate pure players

5. **Normalisation: Pr√©venir hallucinations**
   - Fichier: `canonical/prompts/domain_scoring/lai_domain_scoring.yaml`
   - Changement: Renforcer instructions "EXPLICIT ONLY"
   - Impact: Am√©liore fiabilit√© signaux d√©tect√©s

6. **Ingestion: Augmenter max_content_length**
   - Fichier: `canonical/sources/source_catalog.yaml`
   - Changement: `1000 ‚Üí 2000` pour sources corporate
   - Impact: Capture plus de signaux LAI

### Phase 3: Optimisations Avanc√©es (Impact Faible)

**Priorit√© üü° BASSE**

7. **Scoring: R√©duire poids hybrid_company**
   - Fichier: `canonical/domains/lai_domain_definition.yaml`
   - Changement: `hybrid_company: 10 ‚Üí 5`
   - Impact: R√©duit faux positifs hybrid sans contexte

8. **Ingestion: Ajouter URLs alternatives**
   - Fichier: `canonical/sources/source_catalog.yaml`
   - Changement: Ajouter `alternative_urls` pour sources cl√©s
   - Impact: Capture versions plus riches des news

---

## üéØ MODIFICATIONS CONCR√àTES RECOMMAND√âES

### Modification 1: generic_normalization.yaml

**Localisation**: `canonical/prompts/normalization/generic_normalization.yaml`

**Changement**:
```yaml
# AVANT (ligne ~35)
  4. ENTITY EXTRACTION (ALL explicitly mentioned)
     - Companies: ALL pharmaceutical/biotech company names
     - Molecules: ALL drug/molecule names (INN, generic names)
     - Technologies: ALL technology keywords (e.g., "microspheres", "PEGylation")
     - Trademarks: ALL commercial product names (e.g., "UZEDY¬Æ", "Ozempic")
     - Indications: ALL therapeutic indications/diseases mentioned

# APR√àS
  4. ENTITY EXTRACTION (ALL explicitly mentioned)
     - Companies: ALL pharmaceutical/biotech company names
     - Molecules: ALL drug/molecule names (INN, generic names)
     - Technologies: ALL technology keywords (e.g., "microspheres", "PEGylation")
     - Trademarks: ALL commercial product names (e.g., "UZEDY¬Æ", "Ozempic")
     - Indications: ALL therapeutic indications/diseases mentioned
     - Dosing Intervals: ALL dosing frequency terms explicitly mentioned
       Examples: "once-weekly", "once-monthly", "once every 3 months", "q4w", "q8w", "quarterly"
       CRITICAL: Only extract if EXPLICITLY stated in text
```

**Changement response format**:
```yaml
# AVANT (ligne ~50)
  {
    "summary": "...",
    "extracted_date": "2026-01-27",
    "date_confidence": 0.95,
    "event_type": "partnership",
    "companies_detected": ["Company A", "Company B"],
    "molecules_detected": ["Molecule X"],
    "technologies_detected": ["Technology Y"],
    "trademarks_detected": ["Trademark Z"],
    "indications_detected": ["Indication W"]
  }

# APR√àS
  {
    "summary": "...",
    "extracted_date": "2026-01-27",
    "date_confidence": 0.95,
    "event_type": "partnership",
    "companies_detected": ["Company A", "Company B"],
    "molecules_detected": ["Molecule X"],
    "technologies_detected": ["Technology Y"],
    "trademarks_detected": ["Trademark Z"],
    "indications_detected": ["Indication W"],
    "dosing_intervals_detected": ["once-weekly", "once-monthly"]
  }
```

---

### Modification 2: lai_domain_definition.yaml

**Localisation**: `canonical/domains/lai_domain_definition.yaml`

**Changement 1 - Exclusions**:
```yaml
# AVANT (ligne ~80)
exclusions:
  - "oral tablet"
  - "oral capsule"
  - "oral administration"
  - "transdermal patch"
  - "nasal spray"
  - "sublingual"
  - "inhalation"

# APR√àS
exclusions:
  - "oral tablet"
  - "oral capsule"
  - "oral administration"
  - "transdermal patch"
  - "nasal spray"
  - "sublingual"
  - "inhalation"
  # Manufacturing without LAI context
  - "manufacturing facility"
  - "production plant"
  - "factory construction"
  - "plant expansion"
```

**Changement 2 - Scoring**:
```yaml
# AVANT (ligne ~100)
  event_type_base_scores:
    partnership: 60
    regulatory: 70
    clinical_update: 50
    corporate_move: 40
    financial_results: 30
    other: 20

# APR√àS
  event_type_base_scores:
    partnership: 60
    regulatory: 70
    clinical_update: 50
    corporate_move: 40
    financial_results: 0  # üîß MODIFI√â: 30 ‚Üí 0
    other: 20
```

**Changement 3 - Entity Boosts**:
```yaml
# AVANT (ligne ~110)
  entity_boosts:
    pure_player_company: 25
    trademark_mention: 20
    key_molecule: 15
    hybrid_company: 10
    technology_family: 10

# APR√àS
  entity_boosts:
    pure_player_company: 25
    trademark_mention: 20
    key_molecule: 15
    dosing_interval: 15  # üÜï AJOUT√â
    hybrid_company: 5    # üîß MODIFI√â: 10 ‚Üí 5
    technology_family: 10
```

**Changement 4 - Nouvelle r√®gle contextuelle**:
```yaml
# APR√àS matching_rules (ligne ~95)
matching_rules:
  - id: rule_1
    condition: "1+ strong signal detected"
    action: "match with high confidence"
    
  - id: rule_2
    condition: "2+ medium signals detected"
    action: "match with medium confidence"
    
  - id: rule_3
    condition: "3+ weak signals detected AND 0 exclusions"
    action: "match with low confidence"
    
  - id: rule_4
    condition: "1+ exclusion detected"
    action: "reject (not LAI)"
  
  # üÜï NOUVELLE R√àGLE
  - id: rule_5
    condition: "event_type == 'financial_results' AND signals_detected < 2"
    action: "reject (financial results need explicit LAI content)"
  
  # üÜï NOUVELLE R√àGLE
  - id: rule_6
    condition: "event_type == 'corporate_move' AND manufacturing_terms AND NO technology_signals"
    action: "reject (manufacturing without LAI technology)"
```

---

### Modification 3: lai_domain_scoring.yaml

**Localisation**: `canonical/prompts/domain_scoring/lai_domain_scoring.yaml`

**Changement**:
```yaml
# AVANT (ligne ~10)
system_instructions: |
  You are a specialized AI assistant for evaluating biotech/pharma news relevance 
  to the Long-Acting Injectables (LAI) domain.
  
  Your task: Determine if an item is LAI-relevant and assign a relevance score (0-100).

# APR√àS
system_instructions: |
  You are a specialized AI assistant for evaluating biotech/pharma news relevance 
  to the Long-Acting Injectables (LAI) domain.
  
  Your task: Determine if an item is LAI-relevant and assign a relevance score (0-100).
  
  CRITICAL RULES FOR SIGNAL DETECTION:
  1. Only detect signals EXPLICITLY present in the normalized item
  2. DO NOT infer, assume, or hallucinate signals not provided
  3. If a technology/molecule/term is not in the entities_detected, DO NOT add it
  4. Base your evaluation ONLY on the normalized data provided
  5. When in doubt, be conservative - reject rather than false positive
```

---

### Modification 4: exclusion_scopes.yaml

**Localisation**: `canonical/scopes/exclusion_scopes.yaml`

**Changement - Nouveau scope**:
```yaml
# AJOUTER √† la fin du fichier

stock_market_terms:
  description: "Termes boursiers/indices sans contenu LAI - filtrage bruit corporate"
  scope_type: "exclusion"
  keywords:
    # Indices boursiers
    - "MSCI"
    - "MSCI World"
    - "MSCI Small Cap"
    - "stock index"
    - "market index"
    - "benchmark index"
    
    # Rapports financiers g√©n√©riques
    - "financial calendar"
    - "interim report"
    - "quarterly report"
    - "half-year results"
    - "consolidated results"
    - "earnings report"
    
    # Termes boursiers
    - "market cap"
    - "share price"
    - "stock performance"
    - "trading volume"
    
  notes: |
    Ce scope filtre le bruit boursier des pure players LAI.
    Utilis√© dans ingestion_profiles.yaml > corporate_pure_player_broad.
```

---

### Modification 5: source_catalog.yaml

**Localisation**: `canonical/sources/source_catalog.yaml`

**Changement 1 - Max content length**:
```yaml
# AVANT (sources corporate, ligne ~15)
  - source_key: "press_corporate__medincell"
    # ...
    content_enrichment: "summary_enhanced"
    max_content_length: 1000

# APR√àS
  - source_key: "press_corporate__medincell"
    # ...
    content_enrichment: "full_article"
    max_content_length: 2000
```

**Changement 2 - URLs alternatives** (optionnel, Phase 3):
```yaml
# AJOUTER dans press_sector__endpoints_news
  - source_key: "press_sector__endpoints_news"
    homepage_url: "https://endpts.com/"
    rss_url: "https://endpts.com/feed/"
    # ...
    alternative_urls:  # üÜï AJOUT√â
      - url: "https://www.fiercebiotech.com/"
        match_strategy: "title_similarity"
        priority: "high"
        reason: "FierceBiotech often has more detailed version"
```

---

### Modification 6: ingestion_profiles.yaml

**Localisation**: `canonical/ingestion/ingestion_profiles.yaml`

**Changement**:
```yaml
# AVANT (ligne ~20)
  corporate_pure_player_broad:
    # ...
    signal_requirements:
      mode: "exclude_only"
      exclusion_scopes:
        - "exclusion_scopes.hr_content"
        - "exclusion_scopes.esg_generic"
        - "exclusion_scopes.financial_generic"
        - "exclusion_scopes.anti_lai_routes"
        - "exclusion_scopes.hr_recruitment_terms"
        - "exclusion_scopes.financial_reporting_terms"

# APR√àS
  corporate_pure_player_broad:
    # ...
    signal_requirements:
      mode: "exclude_only"
      exclusion_scopes:
        - "exclusion_scopes.hr_content"
        - "exclusion_scopes.esg_generic"
        - "exclusion_scopes.financial_generic"
        - "exclusion_scopes.anti_lai_routes"
        - "exclusion_scopes.hr_recruitment_terms"
        - "exclusion_scopes.financial_reporting_terms"
        - "exclusion_scopes.stock_market_terms"  # üÜï AJOUT√â
```

---

## üìä IMPACT ATTENDU DES MODIFICATIONS

### M√©triques Avant/Apr√®s (Estimation)

| M√©trique | Avant | Apr√®s | Am√©lioration |
|----------|-------|-------|--------------|
| **Faux positifs** | 5/14 (36%) | 1/14 (7%) | -80% |
| **Faux n√©gatifs** | 2/15 (13%) | 0/15 (0%) | -100% |
| **Pr√©cision** | 64% | 93% | +45% |
| **Bruit newsletter** | √âlev√© | Faible | -70% |

### Cas R√©solus

‚úÖ **Faux n√©gatifs r√©solus**:
- CagriSema (once-weekly d√©tect√©)
- Quince steroid (once-monthly d√©tect√©)

‚úÖ **Faux positifs r√©solus**:
- Eli Lilly manufacturing (exclu)
- MedinCell financial results (score 0)
- Nanexa interim reports (filtr√© ingestion)

‚úÖ **Qualit√© am√©lior√©e**:
- Hallucinations Bedrock r√©duites (instructions renforc√©es)
- Contenu HTML plus complet (max_length augment√©)

---

## ‚ö†Ô∏è RISQUES ET LIMITATIONS

### Risques Identifi√©s

1. **Sur-filtrage possible**
   - Risque: Exclure manufacturing l√©gitime avec tech LAI
   - Mitigation: R√®gle contextuelle (manufacturing OK si technology_signals)

2. **D√©pendance qualit√© extraction HTML**
   - Risque: Dosing intervals dans HTML mal pars√©
   - Mitigation: Augmenter max_content_length

3. **Bedrock peut ignorer nouvelles instructions**
   - Risque: Hallucinations persistent malgr√© prompt renforc√©
   - Mitigation: Tester avec exemples probl√©matiques

### Limitations Accept√©es

- **URLs alternatives**: Impl√©mentation complexe, Phase 3 seulement
- **Hybrid companies**: R√©duction poids peut cr√©er faux n√©gatifs, √† surveiller
- **Financial results**: Score 0 strict, peut manquer annonces LAI dans earnings

---

## üöÄ PLAN D'IMPL√âMENTATION

### √âtape 1: Modifications Fichiers Canonical

```bash
# 1. Cr√©er branche
git checkout -b fix/canonical-improvements-e2e-v13

# 2. Modifier fichiers (ordre recommand√©)
# - canonical/prompts/normalization/generic_normalization.yaml
# - canonical/domains/lai_domain_definition.yaml
# - canonical/prompts/domain_scoring/lai_domain_scoring.yaml
# - canonical/scopes/exclusion_scopes.yaml
# - canonical/sources/source_catalog.yaml
# - canonical/ingestion/ingestion_profiles.yaml

# 3. Commit
git add canonical/
git commit -m "fix: am√©lioration qualit√© ingestion/normalisation/scoring (E2E v13)"
```

### √âtape 2: D√©ploiement et Test

```bash
# 1. Upload canonical vers S3 dev
aws s3 sync canonical/ s3://vectora-inbox-config-dev/canonical/ \
  --profile rag-lai-prod \
  --region eu-west-3

# 2. Test E2E avec cas probl√©matiques
python tests/local/test_e2e_runner.py --new-context "Canonical-Improvements"

# 3. V√©rifier r√©solution des cas
# - CagriSema: dosing_intervals_detected = ["once-weekly"]
# - Quince: dosing_intervals_detected = ["once-monthly"]
# - Eli Lilly: score = 0 (exclu manufacturing)
# - MedinCell financial: score = 0 (financial_results base = 0)
```

### √âtape 3: Validation AWS

```bash
# 1. Promouvoir vers AWS
python tests/aws/test_e2e_runner.py --promote "Canonical-Improvements-Validation"

# 2. Run test AWS
python tests/aws/test_e2e_runner.py --run

# 3. Analyser rapport
# V√©rifier m√©triques: pr√©cision, faux positifs, faux n√©gatifs
```

### √âtape 4: Merge et Documentation

```bash
# 1. Push et PR
git push origin fix/canonical-improvements-e2e-v13

# 2. Merge apr√®s validation

# 3. Documenter changements
# Mettre √† jour docs/architecture/blueprint-v2-ACTUAL-2026.yaml
```

---

## üìù CHECKLIST VALIDATION

**Avant d√©ploiement**:
- [ ] Tous les fichiers canonical modifi√©s
- [ ] Syntaxe YAML valid√©e
- [ ] Scopes r√©f√©renc√©s existent
- [ ] Commit avec message descriptif

**Apr√®s d√©ploiement dev**:
- [ ] Canonical upload√© sur S3 dev
- [ ] Test local avec cas probl√©matiques
- [ ] CagriSema match√© (dosing_intervals d√©tect√©s)
- [ ] Quince match√© (dosing_intervals d√©tect√©s)
- [ ] Eli Lilly rejet√© (manufacturing exclu)
- [ ] MedinCell financial rejet√© (score 0)

**Apr√®s test AWS**:
- [ ] Rapport E2E g√©n√©r√©
- [ ] M√©triques am√©lior√©es vs baseline
- [ ] Aucune r√©gression sur cas valides
- [ ] Blueprint mis √† jour

---

## üéØ CONCLUSION

### R√©sum√© des Am√©liorations

**6 fichiers canonical modifi√©s** pour r√©soudre **7 probl√®mes critiques**:

1. ‚úÖ Extraction dosing intervals (normalisation)
2. ‚úÖ Exclusion manufacturing sans tech (scoring)
3. ‚úÖ Financial results score 0 (scoring)
4. ‚úÖ Filtrage bruit boursier (ingestion)
5. ‚úÖ Pr√©vention hallucinations (prompt)
6. ‚úÖ Contenu HTML enrichi (ingestion)

**Impact attendu**: 
- Pr√©cision: 64% ‚Üí 93% (+45%)
- Faux positifs: -80%
- Faux n√©gatifs: -100%

**Effort**: 
- Modifications: 2-3 heures
- Tests: 1-2 heures
- Total: 1 journ√©e

### Prochaines √âtapes

1. **Imm√©diat**: Impl√©menter Phase 1 (corrections critiques)
2. **Court terme**: Impl√©menter Phase 2 (am√©liorations qualit√©)
3. **Moyen terme**: Impl√©menter Phase 3 (optimisations avanc√©es)
4. **Long terme**: Monitorer m√©triques et ajuster si n√©cessaire

---

**Rapport cr√©√© le**: 2026-02-03  
**Auteur**: Amazon Q Developer  
**Statut**: ‚úÖ Pr√™t pour impl√©mentation  
**Validation**: En attente feedback admin
